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OsteopontinMatrix metalloprotease (MMP)-9 is an endopeptidase associated with the pathogenesis of Duchenne muscular
dystrophy (DMD). The precise function of MMP-9 in DMD has not been elucidated to date. We investigated
the effect of genetic ablation of MMP-9 in the mdxmouse model (mdx/Mmp9−/−). At the early disease stage,
the muscles ofmdx/Mmp9−/−mice showed reduced necrosis and neutrophil invasion, accompanied by down-
regulation of chemokineMIP-2. In addition, muscle regeneration was enhanced, which coincidedwith increased
macrophage inﬁltration and upregulation of MCP-1, and resulted in increased muscle strength. The mdx/
Mmp9−/− mice also displayed accelerated upregulation of osteopontin expression in skeletal muscle at the
acute onset phase of dystrophy. However, at a later disease stage, the mice exhibitedmuscle growth impairment
through altered expression of myogenic factors, and increased ﬁbroadipose tissue. These results showed that
MMP-9might havemultiple functions during disease progression. Therapy targetingMMP-9may improvemus-
cle pathology and function at the early disease stage, but continuous inhibition of this protein may result in the
accumulation of ﬁbroadipose tissues and reduced muscle strength at the late disease stage.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Duchenne muscular dystrophy (DMD) is the most common muscu-
lar dystrophy and is a lethal, X-linked disorder that affects 1 in 3600 to
6000 male births [1]. The disease is caused by a mutation in the DMD
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ra).localized at the sub-sarcolemma and that is a major component of the
dystrophin glycoprotein complex (DGC) which links the cytoskeleton
to the extracellular matrix (ECM) [2–4]. Dystrophin deﬁciency results
in the disruption of the DGC, leading to membrane fragility and subse-
quent muscle ﬁber necrosis with inﬂammation, and replacement of
the skeletal muscle with adipoﬁbrous tissues during chronic degenera-
tion and regeneration cycles. The progressive dystrophic change is ac-
celerated by the impairment of tissue repair and regeneration, along
with muscle ﬁber deterioration; however, the underlying mechanism
remains unclear.
Matrix metalloproteases (MMPs), a family of zinc-dependent endo-
peptidases, are important regulatory proteins in the formation, remod-
eling, and degradation of ECM components in both physiological
processes such as bone morphogenesis and pathological processes
such as tumor progression and metastasis, systemic vascular diseases,
and rheumatoid arthritis [5,6]. The ECM is one of the key players in
the homeostasis and maintenance of muscle ﬁber functional integrity
in the skeletal muscle [7,8]. Furthermore, many non-matrix proteins
such as chemokines, growth factors, and receptors have recently been
revealed to be substrates for MMPs, indicating that MMPs may have a
more complex role, especially in leukocyte recruitment during inﬂam-
mation [9].
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icantly elevated in dystrophic muscle of a dystrophin-deﬁcient DMD
mousemodelmdx compared to wild-type (WT)mice [10]. In particular,
MMP-2 (gelatinase A) andMMP-9 (gelatinase B) were shown to be up-
regulated in the skeletalmuscles ofmdxmice and of the canine X-linked
muscular dystrophy in Japan (CXMDJ)model, predominantly in necrotic
ﬁbers invaded by inﬂammatory cells [11–13]. Furthermore, it has re-
cently been reported that the level of MMP-9 is increased in serum
andmuscle biopsies from DMD patients and correlates with the disease
progression [14]. Therefore, in addition to its role in ECM remodeling in
normal skeletal muscle tissues, MMP-9 has been hypothesized to be in-
volved in the DMD pathomechanism [11,15–17]. Recently, we have
demonstrated that ablation of MMP-2 in mdxmice resulted in the im-
pairment of regenerated muscle ﬁber growth, which coincided with a
decreased expression of vascular endothelial growth factor-A (VEGFA)
and of neuronal nitric oxide synthase (nNOS), implying that MMP-2 is
required for the growth of regeneratedmuscle ﬁbers through angiogen-
esis inmdx skeletal muscle [18].
MMP-9 has been reported to cleave β-dystroglycan (β-DG), a core
component of the DGC, resulting in the disruption of the link between
the ECM and the cell membrane in dystrophin-deﬁcient skeletal muscle
[19,20]. Genetic ablation and pharmacological inhibition of MMP-9 in
mdx mice were shown to reduce skeletal muscle inﬂammation and
ﬁbronecrosis, resulting in improvedmuscle function at the early disease
stage [21,22], and to ameliorate cardiomyopathy and reduceﬁbrosis at a
later disease stage (1-year-old mdxmice) [23]. Furthermore, it has re-
cently been reported that the partial inhibition of MMP-9 caused a re-
duction in pro-inﬂammatory M1 macrophages and an increase in anti-
inﬂammatory M2 macrophages, accompanied by an upregulation of
Notch signaling, improving the muscle regeneration in young mdx
mice [22]. However, little is known about the exact action of MMP-9
in dystrophic muscle.
Osteopontin (OPN), which is a multifunctional matricellular protein
that plays important roles in tissue remodeling following injury [24,25]
is highly expressed in skeletal and cardiacmuscles inmdxmicewhere it
induces increased levels of MMP-9 [23,26,27]. Interestingly, the expres-
sion ofOPN andMMP-9 is similarly high inmicewith cardiotoxin (CTX)-
induced muscle injury [11,28,29]. Recently, the interactions between
MMP-9 and OPN, as well as the elucidation of the function of OPN in
dystrophic muscle, have become an intense area of research focus.
In this study, we investigated the role ofMMP-9 in different stages of
dystrophic muscle, by usingMMP-9 ablation in mdxmice. We focused
our research efforts on the elucidation of its role in chemotaxis, resolu-
tion of inﬂammation, and tissue remodeling in order to assess its poten-
tial as a target for treatment of DMD.
2. Materials and methods
2.1. Mice experiments
All animal experiments were approved by the Animal Experiment
Committee of Shinshu University, Japan, and were carried out in accor-
dance with the institutional guidelines. Wild-type (WT; C57BL/6J) and
Mmp9 knockout (Mmp9−/−; B6.FVB(Cg)-Mmp9tm1Tvu/J; C57BL/6J back-
ground)micewere purchased from the Jackson Laboratory (Bar Harbor,
ME, USA). X-linked muscular dystrophy mdxmice (C57BL/6J-Dmdmdx)
were a gift from the Institute of Neuroscience, National Research Center
of Neurology and Psychiatry (Tokyo, Japan). Mmp9−/− mice were
crossed withmdxmice to generatemdx/Mmp9−/−mice. Themouse ge-
notypes were conﬁrmed by PCR analysis of mouse tail DNA. An mdx-
ampliﬁcation-resistant mutation system assay was used to identify the
control and mdx mice [30]. Mmp9−/− and WT mice were identiﬁed
using the primer sets suggested by Jackson Laboratory. The mice were
housed in plastic cages in a temperature-controlled environment with
a 12 h/12 h light/dark cycle and unlimited access to food and water.
For pathological examination and biochemical analysis, mice wereeuthanized at 2, 4, 8, and 14 weeks, and at 1 year of age, and the tibialis
anterior (TA), diaphragm, and gastrocnemius muscles were dissected.
The muscles were frozen in isopentane cooled with liquid nitrogen
and were stored at−80 °C before they were used for histological anal-
ysis, and protein and RNA isolation.
For CTX experiments, 100 μl of CTX (10 mM in 0.9% NaCl) (Sigma, St
Louis,MO,USA)was slowly injected into the TAmuscles of 14-week-old
WT andMmp9−/−mice using a 27-gauge needle. Micewere euthanized
andmuscles were collected before injection and at 24, 48, and 72 h, and
5, 14, and 28 days after injection.
2.2. Histological analysis and immunohistochemistry
Serial 6-μm cryostat sections were cut from the mid-belly of the
muscle to obtain the largest cross-sectional area (CSA). Sections were
placed on glass slides and air-dried. For morphometric analysis, the sec-
tionswere stainedwith hematoxylin and eosin (H&E). To detectﬁbrosis,
a picrosirius red staining was performed. For immunohistochemistry,
the sections were blocked in 10% goat serum in phosphate-buffered sa-
line (PBS) for 30 min, and incubated overnight at 4 °C with blocking so-
lution that contained the primary antibodies. The sections were washed
brieﬂy with 1× PBS before incubation with the secondary antibody for
1 h at room temperature. After incubation, the sections were washed
three times for 30 min with 1× PBS and mounted in VECTASHIELDme-
dium (Vector Laboratories, Burlingame, CA, USA) containing 4′,6-
diamidino-2-phenylindole (DAPI). The sections were visualized using
a ﬂuorescence microscope (Olympus, Tokyo, Japan), and digital images
were captured and processed with Photoshop CS4 (Adobe, San Jose,
CA, USA) to optimize brightness, contrast, and resolution. The antibodies
used for immunohistochemical staining in this study were as follows:
Alexa Fluor 568-conjugated rat monoclonal anti-CD206 antibody
(1:200; BioLegend, San Diego, CA, USA) was used for direct immunoﬂu-
orescence staining. Ratmonoclonal anti-CD11b (1:200; BDTransduction
Laboratories, San Jose, CA, USA) and rabbit polyclonal anti-MMP-9
(1:1000; Abcam, Cambridge, UK) primary antibodies and Alexa Fluor
488- or Alexa Fluor 568-conjugated (1:500; Life Technologies, Grand Is-
land, NY, USA) secondary antibodies were used for indirect immunoﬂu-
orescence staining. Ratmonoclonal anti-CD11b (1:200; BDTransduction
Laboratories) and rat monoclonal anti-Ly6G (1:50; BD Transduction
Laboratories) antibodies were detected using the VECTASTAIN ABC-
HRP kit (Vector Laboratories, Burlingame, CA, USA) with diaminobenzi-
dine (DAB) as a substrate, according to the manufacturer's instructions.
Rabbit polyclonal anti-OPN (1:300; Rockland Immunochemical,
Gilbertsville, PA, USA) was detected using the VECTASTAIN ABC-AP kit
with Vector Red substrate (Vector Laboratories). Necrotic ﬁbers were
identiﬁed by immunostaining with Alexa 488-conjugated goat anti-
mouse IgG antibody (1:2000; Molecular Probes or Life Technologies).
2.3. Morphometric analysis
Morphometric analysis was performed by determining the CSA of
the perinuclear and the centronuclear muscle ﬁbers in the H&E-
stained TA muscle sections. Necrotic ﬁbers, if present, were omitted
from the analysis. The CSAs were examined using ImageJ software (Na-
tional Institutes of Health, Bethesda, MD, USA): For each muscle, ﬁber
boundaries were determined to evaluate the size and number of the ﬁ-
bers; 1709 to 2523 ﬁbers were analyzed for each genotype. All images
were obtained under identical conditions and at the same magniﬁca-
tion. To create the CSA histograms, histological parameters were evalu-
ated and analyzed as previously described [31].
2.4. Total protein extraction and Western blotting
Muscle protein extraction and Western blot analysis were
performed as previously described [32]. Rabbit polyclonal anti-
myeloperoxidase (MPO) (1:3000; Millipore, Billerica, MA, USA), rabbit
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CA, USA), goat polyclonal anti-OPN (1:3000; Novocastra, Leica
Microsystems, New Castle, UK), rabbit polyclonal anti-collagen type I
(1:1000; Abcam), mouse monoclonal anti-collagen type IV (1:1000;
Santa Cruz Biotechnology), and rabbit polyclonal anti-transforming
growth factor-β (TGF-β) (1:3000; Cell Signaling Technology, Danvers,
MA, USA) primary antibodies and peroxidase-conjugated secondary an-
tibody (Bio-Rad Laboratories, Hercules, CA, USA) were used. The ECL
system (GE Healthcare Life Sciences, Little Chalfont, UK) was used for
Western blotting.
2.5. Gelatin zymography
Frozen tissues were homogenized in extraction buffer (62.5 mM
Tris–HCl [pH 6.8], 2% sodium dodecyl sulfate [SDS], and 10% glycerol),
and total protein content was assessed using a BCA protein assay kit
(Bio-Rad). A gelatin zymography kit (Invitrogen, Carlsbad, CA, USA)
was used to detect gelatinolytic activity. Protein extracts (50 μg) were
mixed with loading buffer and separated by electrophoresis in a
gelatin-containing SDS polyacrylamide gel. The gel was washed with
regenerating buffer and subsequently incubated for 24 h at 37 °C in de-
veloping buffer. The gels were stained with Coomassie brilliant blue
(CBB) and destained with a destaining solution (Bio-Rad). Gelatinolytic
activity was identiﬁed as clear bands on a blue background. Gelatin
zymography detects the activity of both the active and the pro-form of
gelatinolytic MMPs, as exposure to SDS activates the pro-form MMPs
without proteolytic cleavage of the prodomain. Equal protein loading
was conﬁrmed by the CBB staining. Myosin heavy chain (MHC) was
used as a loading control.
2.6. RNA isolation and quantitative reverse transcriptase (qRT)-PCR
Total RNA from frozen muscle tissues was isolated using the RNeasy
Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. RNA was reverse-transcribed into cDNA
using the PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa Bio,
Shiga, Japan). mRNA and 18S ribosomal RNA (18S rRNA) expression
levels were quantiﬁed by using the KOD SYBR qPCR Mix (Toyobo,
Osaka, Japan) with 10 nM of each primer in a ﬁnal volume of 10 μl.
The ampliﬁcation reactions were carried out in duplicate on a
StepOnePlus Real Time PCR system (Applied Biosystems, Foster City,
CA). The thermal cycling conditions used for all primerswere as follows:
2min at 98 ° C, 40 cycles of 10 s at 98 ° C, 10 s at 60 ° C, 30 s at 68 ° C, and
a ﬁnal extension of 10 min at 72 ° C. Per gene, expression in all samples
was quantiﬁed simultaneously. 18S rRNAwas used for normalization of
target gene expression. The primer sequences used for qRT-PCR are
shown in the Supplemental Table S1.
2.7. Hanging wire tests
Mice at 8 weeks and 1 year of age were subjected to a hanging wire
test using a 2-mm diameter metal wire apparatus suspended 35 cm
above the base. The wire test was made up of three trials, with each
trial consisting of an unlimited hanging period followed by a 1-min
pause. The hanging time was recorded for each trial as the time from
the initial grip of the wire with the two forelimbs until the mouse
completely released its grip and fell down. The maximum holding im-
pulse was calculated as follows: holding impulse (s · g) = maximum
hanging time (s) × body mass (g) [33], and was used as a measure of
the tension created by the body weight.
2.8. Creatine kinase activity assay
Blood was collected immediately after the animals were euthanized
via the inferior vena cava using a 23-gauge needle on a 1-ml syringe,
and serum was prepared by centrifugation (1500 ×g, 10 min, 4 °C)The serum creatine kinase (CK) level was determined by using a com-
mercial CK reagent kit (Kanto chemical, Tokyo, Japan).
2.9. Hydroxyproline assay
Collagen and elastin contents of the diaphragm tissues of 1-year-old
mice were evaluated by measuring hydroxyproline using a commercial
assay kit according to the manufacturer's instructions (BioVision, San
Francisco, CA, USA).
2.10. Statistical analysis
Data are expressed as the mean ± SEM. Statistical analysis was
performed using unpaired t-tests for two-group comparisons, and
one-way ANOVA with Bonferroni correction for multiple comparisons.
P-values b 0.05 were considered signiﬁcant. Statistical analyses were
carried out using the GraphPad Prism version 5.0 software (GraphPad
Software, Point Richmond, CA, USA).
3. Results
3.1. Characterization of mdx/Mmp9−/−mice
Mmp9−/−mice were previously reported to display a smaller mus-
cle ﬁber size than WT mice [34]. We conﬁrmed this by histological
and morphometrical analysis of the TA muscles and diaphragms of
WT and Mmp9−/− mice at 4 and 14 weeks of age (Supplementary
Fig. S1). To elucidate the role of MMP-9 in dystrophin-deﬁcient mice,
we generatedmdx/Mmp9−/−mice and subjected them to various anal-
yses. Similar toMmp9−/−mice [5],mdx/Mmp9−/−mice displayed nor-
mal fertility, but their body weight was signiﬁcantly lower than that of
mdx mice at 4–8 weeks and at 1 year of age (Supplementary Fig. S2).
Gelatin zymography of the gastrocnemius skeletal muscle of 8-week-
old WT, Mmp9−/−, mdx, and mdx/Mmp9−/− mice showed that pro-
MMP-9 activitywas detectable only in themdx skeletalmuscle (Supple-
mentary Fig. S3a). Pro-MMP-2 activitywas higher in bothmdx andmdx/
Mmp9−/−mice than in WTmice.MMP-2 expression was lower inmdx/
Mmp9−/− than inmdxmice at 4weeks of age (Supplementary Fig. S3b).
The relative expression of the gene encoding the tissue inhibitor of me-
talloproteinase 1 (TIMP-1), an intrinsic MMP-9 inhibitor, was higher in
mdx/Mmp9−/−mice than inmdxmice at 4 and 8 weeks of age (Supple-
mentary Fig. S3c). The relative expression of the gene encoding TIMP-2,
an inhibitor of MMP-2, was signiﬁcantly higher in mdx/Mmp9−/− than
inmdxmice at 1 year of age (Supplementary Fig. S3d). The relative ex-
pression of the gene encoding TIMP-3, an inhibitor of both MMP-2 and
MMP-9,was signiﬁcantly higher inmdx/Mmp9−/− than inmdxmice at 2
and 8 weeks, and 1 year of age (Supplementary Fig. S3e). These results
suggest that an imbalance in MMP and TIMP expression might enhance
the overexpression of MMP-9 in mdx skeletal muscle.
3.2. Effects of MMP-9 ablation on the dystrophic pathology in mdx mice
Mdxmicewere reported to display an acute onset ofmyoﬁber necro-
sis around 3 weeks of age, a low level of chronic damage by 8 weeks of
age, and a progressive replacement ofmuscle by ﬁbroadipose tissue and
myoﬁber atrophy after 6 months of age [35]. First, we performed a his-
tological analysis of the TA and diaphragm skeletal muscles of WT,
Mmp9−/−, mdx, and mdx/Mmp9−/− mice at 4 and 14 weeks, and
1 year of age. While there was no apparent difference in the H&E stain-
ing of TA and diaphragm tissues betweenmdx andmdx/Mmp9−/−mice
at 4weeks of age (Fig. 1a), the numbers of inﬁltrated inﬂammatory cells
in both muscle tissues were deﬁnitely lower in mdx/Mmp9−/− than in
mdxmice at 14 weeks of age (Fig. 1b). The necrotic area, as determined
by immunoﬂuorescent staining of immunoglobulin G (IgG),was smaller
inmdx/Mmp9−/−mice than inmdxmice between 4 and 14weeks of age
(Supplementary Fig. S4). In addition, the fraction of centronuclear ﬁbers
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Fig. 1.MMP-9 ablation rescuesmdx pathology at 14weeks of age and promotesmuscle regeneration in the early disease stage, but prevents the accumulation ofﬁbroadipose tissues and is
associated with decreased muscle mass and strength at 1 year of age. a, b) Histology of TA muscle and diaphragm cryosections stained with H&E frommdx andmdx/Mmp9−/−mice at 4
(a) and 14 (b) weeks of age. Scale bar: 200 μm. c) Histology of TA muscle and diaphragm cryosections stained with H&E frommdx and mdx/Mmp9−/−mice at 1 year of age. Scale bar:
100 μm. d) Picrosirius red staining of TA muscle and diaphragm from mdx/Mmp9−/− and mdxmice at 1 year of age. Scale bar: 20 μm (left panels), 100 μm (right panels). e) Fraction
(%) of centronucleated ﬁbers in TA muscle of mdx and mdx/Mmp9−/−mice at 4 and 14 weeks of age. f) Serum CK levels ofmdx and mdx/Mmp9−/−mice at 4, 8, and 14 weeks of age.
g) Maximum holding impulse score obtained by a hanging wire test formdx andmdx/Mmp9−/−mice at 1 year of age. Data are presented as mean ± SEM (n= 3 per group). ⁎P b 0.05,
⁎⁎P b 0.01.
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mice at 14 weeks (Fig. 1e), suggesting that muscle regeneration was
promoted by the ablation of MMP-9. The ﬁber size of the CNFs and the
perinuclear ﬁbers (PNFs) was determined for mdx andmdx/Mmp9−/−
mice at 4 and 14weeks of age. No differencewas found between the ge-
notypes of 4-week-old mice (Supplementary Fig. S5a and b). However,at 14weeks, the CNFs ofmdx/Mmp9−/−micewere smaller than those of
mdxmice (Supplementary Fig. S5c and d).
As for the skeletal muscle pathology in older mice, H&E staining and
picrosirius red staining of the TA muscle and of the diaphragm from
1-year-old mice showed a higher accumulation of interstitial
ﬁbroadipose tissue in mdx/Mmp9−/− mice than in mdx mice (Fig. 1c
2174 N. Shiba et al. / Biochimica et Biophysica Acta 1852 (2015) 2170–2182and d). The serum CK level, a marker for muscle damage that depends
on the muscle mass, was lower in mdx/Mmp9−/− than in mdxmice at
14 weeks of age; however, the difference was not signiﬁcant. At 1 year
of age, the CK level was signiﬁcantly reduced in mdx/Mmp9−/− com-
pared to mdx mice (Fig. 1f). The forelimb muscle strength of mdx/
Mmp9−/− mice was greater than that of mdx mice at 8 weeks of age,
but it was drastically reduced in mdx/Mmp9−/− compared to mdx
mice at 1 year of age (Fig. 1g).
Next, we examinedwhetherMMP-9 ablation in themdxmice affect-
ed the processing of β-DG in the skeletal muscle. The β-DG immunore-
activity was lower in 8-week-old mdx andmdx/Mmp9−/−mice than in
WT andMmp9−/−mice (Supplementary Fig. S6a), andwestern blotting
showed that the full-length 43-kDa β-DG (β-DG43) was cleaved into a
30-kDa form (β-DG30) inmdx andmdx/Mmp9−/−mice (Supplementary
Fig. S6b and c). Theβ-DG30 toβ-DG43 expression ratio showed nodiffer-
ence between mdx and mdx/Mmp9−/−mice. In addition, we examined
the protein levels of type IV collagen, a substrate of MMP-9 in TA mus-
cles of 14-week-oldmdx andmdx/Mmp9−/−mice. We observed no dif-
ferences between the protein levels in both genotypes (Supplementary
Fig. S6d and e).
3.3. MMP-9 ablation results in decreased neutrophil and M1 macrophage
inﬁltration in an early-stage mdx mouse muscle
To determine differences in the inﬂammatory cell inﬁltration be-
tween mdx and mdx/Mmp9−/− mice, we investigated the expression
of Ly6G, a marker of neutrophils, in gastrocnemius muscle of mdx and
mdx/Mmp9−/− mice at 4 and 14 weeks of age. Immunohistochemical
staining of muscle sections showed that Ly6G expression in mdx/
Mmp9−/−mice was lower at 4 and 14 weeks of age (Fig. 2a). The rela-
tive expression level of Ly6G was signiﬁcantly lower in mdx/Mmp9−/−
than inmdxmice at 14weeks of age. At 4weeks of age, the Ly6G expres-
sion level was lower inmdx/Mmp9−/− than inmdxmice, but the differ-
encewas not statistically signiﬁcant, probably due to the high variability
of Ly6G expression inmdxmice (Fig. 2b). Western blot analysis of MPO,
another marker for neutrophils showed that the protein level in mdx/
Mmp9−/− mice was signiﬁcantly lower than that in mdx mice at
4 weeks of age. The MPO level at 14 weeks was signiﬁcantly lower
than at 4 weeks of age in both mouse genotypes, but there was no dif-
ference between both genotypes (Fig. 2c).
Next, we examined the expression of the macrophage marker
CD11b in mdx and mdx/Mmp9−/− mice at 4 and 14 weeks of age.
CD11b-positive cells were observed at both 4 and 14 weeks of age,
and their number was lower in mdx/Mmp9−/− than in mdx mice
(Fig. 2a). Macrophages can be divided into two subtypes, M1 and M2,
based on their activation phenotype. M1macrophages are mainly asso-
ciated with muscle degeneration, while M2 macrophages play a role in
muscle regeneration in dystrophic muscle [36]. We examined the local-
ization of M2 macrophages in mdx and mdx/Mmp9−/− mice at 4 and
14 weeks of age, using CD11b as a pan-macrophage marker and
CD206 as a marker for M2 macrophages. In both genotypes, the ratio
of M2 to total macrophages that invaded the tissue was lower at
14 weeks than at 4 weeks of age (Fig. 2d). In 4-week-old tissue, the
ratio of M2 to total macrophages that inﬁltrated the tissue was larger
in mdx/Mmp9−/− than in mdxmice (Fig. 2d). Furthermore, the expres-
sion level of CD11c, a marker for M1 macrophages, was signiﬁcantly
lower in mdx/Mmp9−/− mice than in mdx mice at 14 weeks of age
(Fig. 2e), and the CD206 expression level in mdx/Mmp9−/− mice was
signiﬁcantly higher at 4 weeks, but lower at 14 weeks of age than in
mdxmice (Fig. 2f).
3.4. Association between inﬂammatory cell inﬁltration and
cytokine expression
We examined the mRNA levels of the genes encoding macrophage
inﬂammatory protein-2 (MIP-2) and monocyte chemotactic protein-1(MCP-1) in the gastrocnemius muscle of mdx and mdx/Mmp9−/−
mice. MIP-2 is a neutrophil chemokine designated as a muscle-
produced cytokine (myokine), and MCP-1 is a monocyte/macrophage
recruiting chemokine and myokine [37–41]. The relativeMIP-2 expres-
sion inmuscles ofmdx/Mmp9−/−mice at 4 and 14weeks of agewas sig-
niﬁcantly lower than in mdxmice of the same age (Fig. 3a). TheMCP-1
mRNA level in mdx/Mmp9−/− mice was signiﬁcantly higher than in
mdx mice at 4 weeks of age (Fig. 3b). In addition, we assessed the
mRNA levels of several pro- and anti-inﬂammatory cytokines. The levels
of interferon-γ (IFN-γ) at 4 weeks, tumor necrosis factor-α (TNF-α) at 14
weeks, and interleukin-6 (IL-6) at both 4 and 14 weeks of age, were sig-
niﬁcantly lower in mdx/Mmp9−/− than in mdxmice (Fig. 3c, d, and h),
which was consistent with the observed increase in the proportion of
M2 macrophages. As for the anti-inﬂammatory cytokines, interleukin-4
(IL-4) was signiﬁcantly lower in mdx/Mmp9−/− than in mdx mice at
4 weeks of age (Fig. 3g), but there were no signiﬁcant differences in
IL-13 and IL-10mRNA levels between the two mouse genotypes at ei-
ther time point (Fig. 3e and f).
3.5. Promotion of muscle regeneration and growth impairment in
mdx/Mmp9−/−mice were associated with altered expression of
myogenic factors
Wementioned above that MMP-9 ablation promotedmuscle regen-
eration, but impaired muscle growth, at the early disease stage in mdx
mice. To determine which factors are involved in these alterations in
the pathology of the mdx/Mmp9−/− mice, we investigated the mRNA
levels of the myogenic regulatory factors Pax3, Myf5, MyoD, and
myogenin, at 2, 4, 8, and 14 weeks of age. The mRNA levels of Pax3 and
Myf5 were signiﬁcantly higher in mdx/Mmp9−/− mice than in mdx
mice at 4 weeks of age (supplementary Fig. S7a). Although the MyoD
mRNA levels did not differ between mdx/Mmp9−/− and mdxmice at 4
and 14 weeks of age (Supplementary Fig. S7a), the MyoD protein level
was slightly lower in mdx/Mmp9−/− than in mdxmice at 14 weeks of
age (Supplementary Fig. S7b and c). The mRNA level of myogenin in
mdx/Mmp9−/− mice was lower than that in mdx mice at 14 weeks of
age (Supplementary Fig. S7a).
In addition, we assessed gene expression of the muscle growth fac-
tors myostatin, follistatin, and insulin like growth factor (IGF-1), in mdx
andmdx/Mmp9−/−mice, at 4 and 14weeks of age. No signiﬁcant differ-
ences were observed in the expression of any of the growth factors be-
tween both genotypes (supplementary Fig. S7d). MMP-2 is required for
the growth of regenerated muscle ﬁbers through angiogenesis in
dystrophin-deﬁcient muscle [18,42]. Therefore, we compared the
mRNA levels of the angiogenic factors angiopoietin 1 and 2, VEGF recep-
tor (VEGFR) 1 and 2, VEGFA, and PECAM1 in mdx and mdx/Mmp9−/−
mice at 4 and 14 weeks of age. No differences in expression of any of
these genes were found between both genotypes (Supplementary
Fig. S7e–g). However, VEGFA mRNA levels in mdx and mdx/Mmp9−/−
mice were signiﬁcantly lower than in WT mice at 4 and 14 weeks of
age (Supplementary Fig. S7f).
3.6. MMP-9 ablation induces a transient increase in OPN at the early
disease stage in mdx skeletal muscle
Because OPN contributes to the increased level of MMP-9 in skeletal
muscle in mdxmice [23], and OPN-deﬁciency delays the inﬂammatory
inﬁltration and the onset of muscle regeneration after injury [24], we
examined the expression of OPN in gastrocnemius muscles from mdx
andmdx/Mmp9−/−mice at different stages. OPN expression was upreg-
ulated in both the genotypes at 4 weeks of age, and interestingly, the
OPN level was signiﬁcantly higher in mdx/Mmp9−/−mice than in mdx
mice at the time point, while there was no difference between mdx/
Mmp9−/− and mdx mice at other ages (Fig. 4a). The expression level
of the OPN receptor CD44 was higher in mdx/Mmp9−/− than in mdx
mice until 8 weeks, but lower at 14 weeks and 1 year of age, although
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(Fig. 4b). In accordance with the mRNA data, immunohistochemical
staining showed that the expression of OPN was prominently upregu-
lated in mdx/Mmp9−/−mice at 4 weeks of age compared tomdxmice,
but there was no difference in expression between genotypes at
14 weeks and 1 year of age (Fig. 4c). The protein levels of both the full
length (66 kDa) and the 32-kDa processed form of OPN were signiﬁ-
cantly higher in mdx/Mmp9−/− mice at 4 weeks, but lower at
14 weeks of age, than in mdxmice (Fig. 4d–f).
3.7. Cardiotoxin (CTX) injury induces a decrease in neutrophils and MIP-2
expression and an increase in macrophages and MCP-1 expression in
muscles of Mmp9−/−mice
To determine whether the changes in the inﬁltrated inﬂammatory
cells were related to the deﬁciency in MMP-9, we compared the leuko-
cyte inﬂux in TA muscles between WT and Mmp9−/− mice, at 24, 48,
and 72 h, and 5 days after CTX injection. The H&E staining showed no
signiﬁcant difference between these two genotypes (Fig. 5a). However,
the number of Ly6G-positive cells inﬁltrated inWTmuscle showed larg-
er than inMmp9−/− at 24 h after CTX injury, increasing until 48 h.While
these cells decreased rapidly from the point of 24 h after injury in
Mmp9−/−mice (Fig. 5b). The Ly6G expression level inMmp9−/−mice
was signiﬁcantly lower than that in WT at 24 h after CTX injection
(Fig. 6a). The number of CD11b-positive macrophages increased gradu-
ally until 72 h after CTX injury in WT mice, while inMmp9−/−mice, it
dramatically increased at 72 h (Fig. 5c). The peak level of CD11c atFig. 2. Effects ofMMP-9 ablation on neutrophil andmacrophage inﬁltration in dystrophicmuscl
4 and 14weeks of age. Scale bar: 200 μm. b)mRNA levels of Ly6G inmdx andmdx/Mmp9−/−m
and mdx/Mmp9−/− mice at 4 and 14 weeks of age (upper panel). Relative (to MHC) levels o
and CD206 (red) in mdx and mdx/Mmp9−/− mice at 4 and 14 weeks of age. Scale bar: 100 μm
Mmp9−/−mice at 4 and 14 weeks of age. Data are presented as mean ± SEM (n= 3 per grou24 h after injury was lower in Mmp9−/− than in WT mice (Fig. 6b),
while theCD206 expression level increased until 48h after CTX injection
in both genotypes, with a higher maximum level in Mmp9−/− than in
WT mice (Fig. 6c).
Further, we examined the mRNA levels of MIP-2 and MCP-1 in TA
muscle at 24, 48, and 72 h, and 5, 14, and 28 days after CTX injury.
The MIP-2 expression in both WT and Mmp9−/− mice peaked signiﬁ-
cantly at 24 h after injury, albeit at a signiﬁcantly higher level in WT
than in Mmp9−/− mice (Fig. 6d). The MCP-1 levels in both WT and
Mmp9−/− mice similarly peaked at 24 h after injury, but decreased
gradually at later time points, and the expression level at 24 h was sig-
niﬁcantly higher inMmp9−/−mice than in WTmice (Fig. 6e). In accor-
dance with previously reported results [28,29], the OPN expression
increased dramatically upon CTX injury in muscle tissues from both ge-
notypes. However, the expression in Mmp9−/− mice peaked at 48 h
after injury and was signiﬁcantly higher than the peak level in WT
mice at 24 h, suggesting that MMP-9 ablation delays the upregulation
of OPN in injured muscles (Fig. 6f).
3.8. MMP-9 ablation leads to an increased accumulation of connective
tissue in skeletal muscle, without elevated TGF-β expression, in 1-year-old
mdx mice
To study muscle pathology in the late disease stage further, we
assessed the ﬁbrosis in the diaphragm tissue of 1-year-old mice. Immu-
nohistochemistry showed an increase in type I collagen in the dia-
phragm tissue of mdx/Mmp9−/− mice at 1 year compared to mice ate. a) Immunohistochemical staining of Ly6G and CD11b inmdx andmdx/Mmp9−/−mice at
ice at 4 and 14weeks of age (relative to 18S rRNA). c)Western blot probed forMPO inmdx
f MPO shown in upper panel (lower panel). d) Immunoﬂuorescence of CD11b (green)
. e, f) Relative (to 18S rRNA) mRNA levels of CD11c (e) and CD206 (f) in mdx and mdx/
p). ⁎P b 0.05, ⁎⁎P b 0.01.
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higher than in 1-year-old mdx mice (Fig. 7a). The protein level for
type I collagen, but not type IV collagen, was signiﬁcantly higher in
mdx/Mmp9−/− than inmdxmice at 1 year of age (Fig. 7b and c). The hy-
droxyproline assay showed increased connective tissue including colla-
gen, gelatin, and elastin in the diaphragm tissue of mdx/Mmp9−/−
compared with mdx mice at 1 year of age (Fig. 7d). The protein level
of the 25-kDa activated form of TGF-β (TGF-β25) was signiﬁcantly
lower in mdx/Mmp9−/− than in mdxmice, while the expression of the
50-kDa latent form of TGF-β (TGF-β50) in both genotypes were at the
same level at 1 year of age (Fig. 7e). ThemRNA level of TGF-βwas signif-
icantly reduced in mdx/Mmp9−/− relative to mdxmice at 14 weeks of
age, but there was no difference at 1 year of age (data not shown).
The mRNA levels of another ﬁbrogenic factor, platelet-derived growth
factor (PDGF), was lower in mdx/Mmp9−/− mice than in mdx mice at
1 year of age (Fig. 7f).4. Discussion
In this study, we investigated the role of MMP-9 in skeletal muscle
in the mdx mouse model by genetic ablation of MMP-9. Gene expres-
sion analysis of TIMPs and MMP-2 in the dystrophic muscle of mdx/
Mmp9−/− mice suggested an altered balance of expression of these
proteins that might enhance the overexpression of MMP-9 in mdx
muscle. We showed that the ablation of MMP-9 induced decreased
muscle necrosis and augmented muscle ﬁber regeneration, resulting
in improved muscle strength at the early disease stage, which was
consistent with previously reported ﬁndings [21–23]. However, long-
term MMP-9-deﬁciency was shown to induce an increased accumula-
tion of adipoﬁbrous tissue in the skeletal muscle, resulting in muscle
atrophy and weakness in mdx mice at the late dystrophy stage. As
MMP-9 was reported to cleave β-DG, which led to muscle degenera-
tion [19,43], we assessed skeletal muscle degradation and β-DG
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not signiﬁcantly reduced by MMP-9 ablation. We previously
showed that MMP-2 did not play a role in β-DG processing in mdxmice [18]. Taken together, these ﬁndings imply that protease(s) other
than MMP-9 and MMP-2 are responsible for β-DG processing in mdx
mice.
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DMD stage in mdx and mdx/Mmp9−/− mice revealed reduced neutro-
phil inﬁltration, which was associated with decreased muscle necrosis
and lower expression of the neutrophil recruiting chemokineMIP-2, in
mdx/Mmp9−/−mice compared to mdxmice during the early phase of
myoﬁber necrosis. These results are consistent with the previous ﬁnd-
ing that antibody depletion of host neutrophils ameliorates the dystro-
phic pathology in young mdx mice [44]. In contrast, MMP-9 ablation
caused an increase in macrophage inﬁltration with elevated expression
of MCP-1 in mdx/Mmp9−/− compared to mdxmice of the same phase.
Furthermore, we observed an increase in the proportion of M2 macro-
phages at 4 weeks of age, which was similar to the previously reported
ﬁnding of an increase in the population of M2 macrophages in strain
C57BL/10 mdx/Mmp9+/− mice at 8 weeks of age [22]. Macrophages
can play both deleterious and beneﬁcial roles in the pathogenesis of
DMD inmdxmice and can adopt various phenotypes in response to dif-
ferent stimuli [36,45]. M1macrophages, activated by pro-inﬂammatory
Th1 cytokines, including IFN-γ, can promote muscle ﬁber injury indi-
rectly through the production of nitric oxide and inﬂammatory cyto-
kines such as TNF-α and IL-6, or directly by phagocytosis [45]. Our
ﬁnding that IFN-γ at 4 weeks, and TNF-α and IL-6 at 14 weeks of age,
were expressed at a signiﬁcantly lower level in muscle tissues of mdx/
Mmp9−/− than in those ofmdxmice corroborated the relative predom-
inance of M2 macrophage invasion in mdx/Mmp9−/− mice. The M2
macrophage phenotype is induced by IL-4 and IL-13 via the production
of anti-inﬂammatory cytokines such as IL-10 [46], and reduces inﬂam-
mation in the dystrophic muscle and attenuates myoﬁber injury in
mdxmice [36]. Activated M2 macrophages promote muscle regenera-
tion by stimulating the proliferation of myogenic progenitor (satellite)
cells in mdxmice [36,45]. The modulation of the proportion of M1 and
M2 macrophages can thus inﬂuence the disease course and severity of
the DMD dystrophinopathy.
Neutrophils are key players in the acute phase of inﬂammation asso-
ciated with muscle injury, but they can also exaggerate muscle damage
[47,48]. In particular, MPO may play a critical role in neutrophil-
mediated damage via the generation of oxidative stress [47,49]. In the
process of resolution of inﬂammation, it is important that abrogationof the chemokine signaling blocks a continued neutrophil inﬁltration
and that macrophages clear apoptotic neutrophils and other cells from
the sites of inﬂammation [47,50]. Ablation of MMP-9 was associated
with decreased neutrophil inﬁltration and improvement of pathology
in a mouse model of ischemic heart disease [51]. Furthermore, IL-8, a
homologue of MIP-2, has been reported to be a substrate of MMP-9,
which processes IL-8 to its active form [52]. In this study, the mecha-
nism by whichMIP-2 expression and neutrophil inﬁltration in skeletal
muscle were reduced in mdx/Mmp9−/− mice compared to mdx mice,
was not fully investigated, however, it is likely that proteolytic activa-
tion of MIP-2 by MMP-9 might contribute to the change in chemotaxis
in dystrophic muscle.
Another interesting ﬁnding in this study was that OPN expression in
mdx/Mmp9−/−mice was signiﬁcantly higher than in mdxmice during
the acute phase of dystrophic pathology, at 4weeks of age. OPN is an in-
triguingmultifunctional protein that is highly expressed in inﬂammato-
ry cells, endothelial cells, and myoﬁbers in dystrophic and injured
muscle [28,29,53] and promotes acute inﬂammatory inﬂux leading to
an early resolution of inﬂammation and muscle regeneration [24,25].
In addition, it has been reported that decreased expression of OPN led
to greater muscle weakness in patients with DMD [54]. On the other
hand, ablation of OPN inmdxmice resulted in reduced ﬁbrosis and de-
creased muscle impairment, suggesting that chronic OPN overexpres-
sion is deleterious to the dystrophic muscle [26]. Therefore, transient
OPN overexpression induced by inﬂammation may be beneﬁcial for
muscle regeneration, whereas chronic overexpression and processing
of OPN may lead to chronic inﬂammation of injured muscles and even-
tually to ﬁbrosis and functional impairment [25]. Hence, it is quite prob-
able that the enhanced dynamic change in OPN expression at the early
disease stage might play a part in improving the dystrophic pathology
in mdx/Mmp9−/−mice.
We found that MMP-9 ablation in mdx mice promoted muscle re-
generation but impaired muscle cell growth at the early stage of the
dystrophy. The expression of myogenic factors involved in the early
phase of muscle regeneration such as Pax3 andMyf5 were increased in
mdx/Mmp9−/− mice at 4 weeks of age, while angiogenic and growth
factors were not differentially expressed. MCP-1 and its receptor C-C
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important role in muscle regeneration [39,55,56]. Previous studies sug-
gested that acute and strong OPN expression is required for normal
muscle regeneration after single severe injury [24] and that CD44, a
major receptor for OPN and hyaluronan located on myoblasts, is a key
regulator of myoblast migration and differentiation [57]. Therefore,
the transient upregulation of these distinct myogenic factors during
the acute dystrophy phase might account for the improved muscle re-
generation inmdx/Mmp9−/−mice at this stage. Simultaneously, we ob-
served impaired growth of the regenerated muscle in mdx/Mmp9−/−
mice. It has been reported that MMP-9 is involved in angiogenesis, as
Mmp9−/−mice demonstrated a reduction in angiogenesis [58]. We hy-
pothesized that the correlation between the regeneratedmuscle growth
impairment and the reduction in angiogenesis in the mdx/Mmp9−/−
micemight allowus to identify the involved angiogenesis or growth fac-
tors. However,we foundno signiﬁcant differences in themRNA levels of
the examined angiogenic and growth factors in mdx/Mmp9−/− com-
pared tomdxmice. It is conceivable that thedownregulation ofmyogen-
ic factors involved in latemyogenesis such asMyoD andmyogenin plays
a role in growth impairment, and is consistent with the decreased
expression levels of proinﬂammatory cytokines including IL-6 and
TNF-α, which are reported to promote regenerated ﬁber maturation
by upregulating these myogenic factors [59], in mdx/Mmp9−/−mice at
14 weeks of age.
To assess whether the decrease in neutrophils and the increase in
macrophages is speciﬁc to the ablation of MMP-9 with dystrophin-
deﬁciency, we examined the histopathology of muscles injured by CTX
inMmp9−/−mice. Interestingly, neutrophil inﬁltration was signiﬁcantly
decreased compared to WT, while macrophage invasion was enhanced
inMmp9−/−mice after injury, similar to the ﬁndings in the 4-week-old
mdx/Mmp9−/− mice. In addition, we observed a downregulation of
MIP-2 and anupregulation ofMCP-1 in the acutely injuredmuscle, similar
to our ﬁndings inmdxmice at 4 week of age, which might play a role in
the histopathological changes. In addition, the lack ofMMP-9 delayed the
drastic upregulation of OPN by CTX injury observed in WT mice. The ex-
pression ofMMP-9 and OPN had been previously reported to transiently
increase upon CTX-induced muscle injury in WT mice [11,28,29]. These
ﬁndings suggest that MMP-9 might regulate OPN expression directly or
indirectly in dystrophic, as well as in acutely injured muscle tissues.
Our study demonstrated that mdx/Mmp9−/−mice developed more
excessive ﬁbrosis with a signiﬁcantly increased protein level of type I
collagen in skeletal muscle thanmdxmice during the later stage of dis-
ease (at 1 year).MMP-9 has been reported to degrade variousﬁbrogenic
ECM components such as collagen and proteoglycans [60–62]. On the
other hand, it has been reported that MMP-9 activates TGF-β through
proteolytic cleavage of the inhibitory domain [63], and that inhibition
of MMP-9 reduces the active TGF-β protein level in the diaphragm of
mdxmice at 14weeks of age [21]. In addition, a previous study reported
that ablation of MMP-9 reduced cardiac ﬁbrosis with improved heart
function in 1-year-old mdx mice, although TGF-β was not assessed in
the study and the precise underlying mechanism remained unclear
[23]. In this study, the protein level of the active form of TGF-β
(25 kDa) at 1 year of age and the mRNA level of TGF-β at 14 weeks of
age were lower in the skeletal muscle of mdx/Mmp9−/− mice than in
mdx mice, consistent with the prospective reduction in activation of
TGF-β. In addition, the mRNA levels of other important ﬁbrogenic fac-
tors including PDGF and OPN (data not shown) were also lower in
mdx/Mmp9−/−mice than in mdxmice at 1 year of age, suggesting that
these proteins might not be directly involved in the pathology at this
stage. Taken together, these results imply that MMP-9 plays an impor-
tant role in degrading ECM components causing tissue ﬁbrosis in aged
mdx skeletalmuscle. However,whether the exaggeratedmuscle ﬁbrosis
in agedmdx/MMP9−/−mice is due to prolonged inhibition of MMP-9 or
a stage-speciﬁc effect of MMP-9 inhibition cannot be clariﬁed in this
study. Further experiments using a MMP-9 speciﬁc chemical inhibitor
are required to distinguish the two possibilities.In summary, we revealed that the principal role of MMP-9 in dystro-
phic muscle is biphasic; MMP-9 delays the resolution of inﬂammation
and exacerbates the dystrophic pathology in the early disease stage,
while in the later stage, MMP-9 plays a critical role in suppressing the
accumulation of ﬁbroadipose tissue. It is known that corticosteroids in-
crease muscle strength in DMD patients [64], and that MMP-9 is
inhibited by corticosteroids [65,66]. Therefore,MMP-9 could be a prom-
ising therapeutic target for the treatment of DMD; however, it is impor-
tant to carefully consider the disease stage and conditions before clinical
application.
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